Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update
March 8, 2016 7:33 AM ESTNet Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer
Strong Cash Position of $76.3 Million Projected to Fund Operations into 2018
Special Protocol Assessment for Phase III Clinical Trials of Fabry Disease Filed
Fabry Disease Phase III Trials Expected to Start in First Half of 2016
Two Proof of Concept Studies in Patients of AIR DNaseTM and Oral antiTNF Planned to Start in Mid 2016
CARMIEL, Israel, March 08, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,... More
